Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

  title={Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.},
  author={Aryan Sarparast and Kelan Thomas and Benjamin J. Malcolm and Christopher S. Stauffer},
RATIONALE & OBJECTIVES  ± 3,4-Methylenedioxymethamphetamine (MDMA) and psilocybin are currently moving through the US Food and Drug Administration's phased drug development process for psychiatric treatment indications: posttraumatic stress disorder and depression, respectively. The current standard of care for these disorders involves treatment with psychiatric medications (e.g., selective serotonin reuptake inhibitors), so it will be important to understand drug-drug interactions between MDMA… 
3 Citations

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

There is strong neurobiological plausibility for the hypothesis that chronic SSRI use dampens response to MDMA-assisted therapy, although current knowledge in the field is limited and primarily relates to acute pharmacodynamic interactions.

Psychedelic therapy for body dysmorphic disorder

In this opinion piece we propose the investigation of psychedelic-assisted psychotherapy for the treatment of body dysmorphic disorder (BDD). BDD is a psychiatric disorder characterised by



What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review

A systematic review of the clinical trials conducted so far regarding the therapeutic effects of psilocybin on psychiatric disorders suggests a substantial therapeutic potential for this compound.

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Recent exposure to antidepressant drugs that target reuptake transporters may reduce treatment response to MDMA-assisted psychotherapy.

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants and olanzapine demonstrated increased odds ratios for the reported risk of death among MDMA users.

MDMA interactions with pharmaceuticals and drugs of abuse

This article provides an overview of the MDMA-DIs with pharmaceuticals and drugs of abuse and points out the relevance of MDMA-DI’s when MDMA is co-administered with Pharmaceuticals that are metabolized by the CYP2D6 due to MDMA inhibitory action.

Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies

Although MDMA plasma concentration was the strongest predictor, several personality traits and mood state variables additionally explained variance in the response to MDMA, confirming that both pharmacological and non-pharmacological variables influence the response of MDMA.

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Psilocybin-assisted therapy efficacy and safety appear promising, but more robust clinical trials will be required to support FDA approval and identify the potential role in clinical psychiatry.

Serotonin toxicity of serotonergic psychedelics.

Signs and symptoms of ST are described, mechanisms of ST risk are characterized, what is known about serotonergic psychedelic drug interactions are summarized, and potential management strategies are outlined.

Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics

It seems that paroxetine could interact with MDMA at pharmacodynamic (serotonin transporter) and pharmacokinetic (CYP2D6 metabolism) levels, whereas MDMA alone produced the prototypical effects of the drug.